Replimune Group, Inc. develops immunotherapy to fight against cancer by activating the immune system with its unique platform. Their first candidate is RP1, a selectively replicating version of herpes simplex virus 1, which has entered Phase I/II clinical trials and is being developed for a range of solid tumors; RP2 and RP3 are also under development. The biotechnology company was founded in 2015 and is located in Woburn, Massachusetts.